Natera, Inc. $NTRA Stock: Saxony Capital Management LLC Grows Position

Saxony Capital Management LLC grew its position in Natera, Inc. (NASDAQ:NTRA) by 256.0% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 3,297 shares of the medical research company’s stock after buying an additional 2,371 shares during the quarter. Saxony Capital Management LLC’s holdings in Natera were worth $1,363,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of Natera during the second quarter worth approximately $2,962,770,000. Castle Hook Partners LP raised its stake in Natera by 24.1% in the 4th quarter. Castle Hook Partners LP now owns 2,167,869 shares of the medical research company’s stock valued at $496,637,000 after purchasing an additional 420,621 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in Natera by 1.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company’s stock valued at $238,334,000 after purchasing an additional 11,793 shares during the last quarter. Maverick Capital Ltd. raised its stake in Natera by 24.1% in the 1st quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company’s stock valued at $234,315,000 after purchasing an additional 227,605 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Natera by 10.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company’s stock valued at $226,220,000 after purchasing an additional 80,440 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Solomon Moshkevich sold 15,160 shares of Natera stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $326.89, for a total transaction of $4,955,652.40. Following the transaction, the insider owned 110,859 shares in the company, valued at approximately $36,238,698.51. This trade represents a 12.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Brophy sold 2,419 shares of the business’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $253.96, for a total value of $614,329.24. Following the transaction, the chief financial officer directly owned 54,295 shares in the company, valued at $13,788,758.20. This trade represents a 4.27% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 52,985 shares of company stock worth $16,119,137. 5.05% of the stock is owned by corporate insiders.

Natera Price Performance

Shares of Natera stock opened at $404.79 on Friday. The stock has a market cap of $58.35 billion, a P/E ratio of -297.64 and a beta of 1.50. The stock’s 50 day simple moving average is $356.78 and its 200-day simple moving average is $274.42. Natera, Inc. has a 1-year low of $178.01 and a 1-year high of $437.41.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The business’s revenue was up 37.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.74) earnings per share. As a group, research analysts expect that Natera, Inc. will post -1.02 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

NTRA has been the topic of several recent research reports. Stephens lifted their target price on shares of Natera from $305.00 to $350.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Citigroup upped their target price on shares of Natera from $365.00 to $480.00 and gave the stock a “buy” rating in a report on Tuesday, October 6th. Wells Fargo & Company increased their target price on shares of Natera from $220.00 to $284.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Guggenheim increased their target price on shares of Natera from $360.00 to $475.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Finally, Piper Sandler raised their price target on shares of Natera from $249.00 to $363.50 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $368.69.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to assess genetic and disease-related risks. The company uses technologies including cell-free DNA analysis and next-generation sequencing to support clinical decision-making in reproductive health, oncology and organ transplantation.

Its reproductive health offerings include Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test that evaluates whether prospective parents carry genetic variants associated with inherited disorders.